The Last-Minute Phone Call That Spurred Teva-Allergan Deal

Updated on

Teva Purchasing Allergan's Generics Unit in $40.5B Deal

The chief executive officer of Teva Pharmaceuticals Industries Ltd., Erez Vigodman, was just hours away from increasing his hostile bid for Mylan Inc. when he got the news he’d waited months to hear. Brent Saunders, his counterpart at Botox-maker Allergan Plc, told him: Forget Mylan. Let’s do lunch.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.